Dipeptidyl Peptidase-4 Inhibitors and Cardiovascular Outcomes: Meta-Analysis of Randomized Clinical Trials with 55,141 Participants
出版年份 2014 全文链接
标题
Dipeptidyl Peptidase-4 Inhibitors and Cardiovascular Outcomes: Meta-Analysis of Randomized Clinical Trials with 55,141 Participants
作者
关键词
-
出版物
Cardiovascular Therapeutics
Volume 32, Issue 4, Pages 147-158
出版商
Wiley
发表日期
2014-04-21
DOI
10.1111/1755-5922.12075
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Heart failure and dipeptidyl peptidase-4 inhibitors
- (2014) Henry Krum et al. EUROPEAN JOURNAL OF HEART FAILURE
- Cardiovascular outcome trials in type 2 diabetes and the sulphonylurea controversy: Rationale for the active-comparator CAROLINA trial
- (2013) Julio Rosenstock et al. Diabetes & Vascular Disease Research
- Cardiovascular safety of the dipetidyl peptidase-4 inhibitor alogliptin in type 2 diabetes mellitus
- (2013) W. B. White et al. DIABETES OBESITY & METABOLISM
- Cardiovascular effects of gliptins
- (2013) André J. Scheen Nature Reviews Cardiology
- Alogliptin after Acute Coronary Syndrome in Patients with Type 2 Diabetes
- (2013) William B. White et al. NEW ENGLAND JOURNAL OF MEDICINE
- Saxagliptin and Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus
- (2013) Benjamin M. Scirica et al. NEW ENGLAND JOURNAL OF MEDICINE
- Meta-Analysis of Effect of Dipeptidyl Peptidase-4 Inhibitors on Cardiovascular Risk in Type 2 Diabetes Mellitus
- (2012) Harshal R. Patil et al. AMERICAN JOURNAL OF CARDIOLOGY
- Effects of saxagliptin added to sub-maximal doses of metformin compared with uptitration of metformin in type 2 diabetes: the PROMPT study
- (2012) Michel P. Hermans et al. CURRENT MEDICAL RESEARCH AND OPINION
- Effect of saxagliptin as add-on therapy in patients with poorly controlled type 2 diabetes on insulin alone or insulin combined with metformin
- (2012) Anthony H. Barnett et al. CURRENT MEDICAL RESEARCH AND OPINION
- Initial combination of linagliptin and metformin improves glycaemic control in type 2 diabetes: a randomized, double-blind, placebo-controlled study
- (2012) T. Haak et al. DIABETES OBESITY & METABOLISM
- Efficacy and safety of initial combination therapy with sitagliptin and pioglitazone in patients with type 2 diabetes: a 54-week study
- (2012) K. H. Yoon et al. DIABETES OBESITY & METABOLISM
- Linagliptin monotherapy in type 2 diabetes patients for whom metformin is inappropriate: an 18-week randomized, double-blind, placebo-controlled phase III trial with a 34-week active-controlled extension
- (2012) A. H. Barnett et al. DIABETES OBESITY & METABOLISM
- Dipeptidyl peptidase-4 inhibitors and cardiovascular risk: a meta-analysis of randomized clinical trials
- (2012) M. Monami et al. DIABETES OBESITY & METABOLISM
- Incretins as a novel therapeutic strategy in patients with diabetes and heart failure
- (2012) M. A. Khan et al. HEART FAILURE REVIEWS
- 2-year efficacy and safety of linagliptin compared with glimepiride in patients with type 2 diabetes inadequately controlled on metformin: a randomised, double-blind, non-inferiority trial
- (2012) Baptist Gallwitz et al. LANCET
- The efficacy and safety of the dipeptidyl peptidase-4 inhibitor saxagliptin in treatment-naive patients with type 2 diabetes mellitus: a randomized controlled trial
- (2012) Robert Frederich et al. Diabetology & Metabolic Syndrome
- Thiazolidinediones and Risk of Heart Failure in Patients with or at High Risk of Type 2 Diabetes Mellitus
- (2011) Adrian V. Hernandez et al. American Journal of Cardiovascular Drugs
- Safety and efficacy of saxagliptin in combination with submaximal sulphonylurea versus up-titrated sulphonylurea over 76 weeks
- (2011) Antonio R Chacra et al. Diabetes & Vascular Disease Research
- Safety and efficacy of saxagliptin added to thiazolidinedione over 76 weeks in patients with type 2 diabetes mellitus
- (2011) Priscilla L Hollander et al. Diabetes & Vascular Disease Research
- Initial combination therapy with saxagliptin and metformin provides sustained glycaemic control and is well tolerated for up to 76 weeks
- (2011) A. Pfützner et al. DIABETES OBESITY & METABOLISM
- Alogliptin as a third oral antidiabetic drug in patients with type 2 diabetes and inadequate glycaemic control on metformin and pioglitazone: a 52-week, randomized, double-blind, active-controlled, parallel-group study
- (2011) E. Bosi et al. DIABETES OBESITY & METABOLISM
- Efficacy and safety of initial combination therapy with linagliptin and pioglitazone in patients with inadequately controlled type 2 diabetes: a randomized, double-blind, placebo-controlled study
- (2011) R. Gomis et al. DIABETES OBESITY & METABOLISM
- Linagliptin monotherapy provides superior glycaemic control versus placebo or voglibose with comparable safety in Japanese patients with type 2 diabetes: a randomized, placebo and active comparator-controlled, double-blind study
- (2011) R. Kawamori et al. DIABETES OBESITY & METABOLISM
- Efficacy and safety of saxagliptin in drug-naïve Asian patients with type 2 diabetes mellitus: a randomized controlled trial
- (2011) Chang Yu Pan et al. DIABETES-METABOLISM RESEARCH AND REVIEWS
- Efficacy and safety of linagliptin in persons with Type 2 diabetes inadequately controlled by a combination of metformin and sulphonylurea: a 24-week randomized study1
- (2011) D. R. Owens et al. DIABETIC MEDICINE
- Efficacy and safety of sitagliptin and the fixed-dose combination of sitagliptin and metformin vs. pioglitazone in drug-naïve patients with type 2 diabetes
- (2011) A. Pérez-Monteverde et al. INTERNATIONAL JOURNAL OF CLINICAL PRACTICE
- Long-term treatment with the dipeptidyl peptidase-4 inhibitor saxagliptin in patients with type 2 diabetes mellitus and renal impairment: a randomised controlled 52-week efficacy and safety study
- (2011) M. Nowicki et al. INTERNATIONAL JOURNAL OF CLINICAL PRACTICE
- Rosiglitazone Revisited
- (2010) Steven E. Nissen et al. ARCHIVES OF INTERNAL MEDICINE
- The Oral Dipeptidyl Peptidase-4 Inhibitor Sitagliptin Increases Circulating Endothelial Progenitor Cells in Patients With Type 2 Diabetes: Possible role of stromal-derived factor-1
- (2010) G. P. Fadini et al. DIABETES CARE
- Efficacy and safety of sitagliptin and metformin as initial combination therapy and as monotherapy over 2 years in patients with type 2 diabetes
- (2010) D. Williams-Herman et al. DIABETES OBESITY & METABOLISM
- Efficacy and safety of treatment with sitagliptin or glimepiride in patients with type 2 diabetes inadequately controlled on metformin monotherapy: a randomized, double-blind, non-inferiority trial
- (2010) R. Arechavaleta et al. DIABETES OBESITY & METABOLISM
- Safety and efficacy of linagliptin as add-on therapy to metformin in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled study
- (2010) M.-R. Taskinen et al. DIABETES OBESITY & METABOLISM
- The global burden of diabetes and its complications: an emerging pandemic
- (2010) Dieren Susan van et al. EUROPEAN JOURNAL OF CARDIOVASCULAR PREVENTION & REHABILITATION
- Interactive Hemodynamic Effects of Dipeptidyl Peptidase-IV Inhibition and Angiotensin-Converting Enzyme Inhibition in Humans
- (2010) Annis Marney et al. HYPERTENSION
- Safety and efficacy of treatment with sitagliptin or glipizide in patients with type 2 diabetes inadequately controlled on metformin: a 2-year study
- (2010) T. Seck et al. INTERNATIONAL JOURNAL OF CLINICAL PRACTICE
- Saxagliptin is non-inferior to glipizide in patients with type 2 diabetes mellitus inadequately controlled on metformin alone: a 52-week randomised controlled trial
- (2010) B. Göke et al. INTERNATIONAL JOURNAL OF CLINICAL PRACTICE
- Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trial
- (2010) Richard M Bergenstal et al. LANCET
- Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin added to pioglitazone in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled study
- (2009) Richard E. Pratley et al. CURRENT MEDICAL RESEARCH AND OPINION
- Effect of saxagliptin monotherapy in treatment-naïve patients with type 2 diabetes
- (2009) J. Rosenstock et al. CURRENT MEDICAL RESEARCH AND OPINION
- The Efficacy and Safety of Saxagliptin When Added to Metformin Therapy in Patients With Inadequately Controlled Type 2 Diabetes With Metformin Alone
- (2009) R. A. DeFronzo et al. DIABETES CARE
- Alogliptin added to insulin therapy in patients with type 2 diabetes reduces HbA1cwithout causing weight gain or increased hypoglycaemia
- (2009) J. Rosenstock et al. DIABETES OBESITY & METABOLISM
- Saxagliptin given in combination with metformin as initial therapy improves glycaemic control in patients with type 2 diabetes compared with either monotherapy: a randomized controlled trial
- (2009) M. Jadzinsky et al. DIABETES OBESITY & METABOLISM
- Comparison of vildagliptin and pioglitazone in patients with type 2 diabetes inadequately controlled with metformin
- (2009) G. Bolli et al. DIABETES OBESITY & METABOLISM
- Comparison of vildagliptin and metformin monotherapy in elderly patients with type 2 diabetes: a 24-week, double-blind, randomized trial
- (2009) A. Schweizer et al. DIABETES OBESITY & METABOLISM
- Fifty-two-week efficacy and safety of vildagliptin vs. glimepiride in patients with type 2 diabetes mellitus inadequately controlled on metformin monotherapy
- (2009) E. Ferrannini et al. DIABETES OBESITY & METABOLISM
- Vildagliptin plus metformin combination therapy provides superior glycaemic control to individual monotherapy in treatment-naive patients with type 2 diabetes mellitus
- (2009) E. Bosi et al. DIABETES OBESITY & METABOLISM
- Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin in patients with type 2 diabetes inadequately controlled by glyburide monotherapy
- (2009) R. E. Pratley et al. DIABETES OBESITY & METABOLISM
- Efficacy and safety of monotherapy of sitagliptin compared with metformin in patients with type 2 diabetes
- (2009) P. Aschner et al. DIABETES OBESITY & METABOLISM
- Efficacy and safety of sitagliptin when added to insulin therapy in patients with type 2 diabetes
- (2009) T. Vilsbøll et al. DIABETES OBESITY & METABOLISM
- Efficacy and safety of sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes
- (2008) Itamar Raz et al. CURRENT MEDICAL RESEARCH AND OPINION
- Efficacy and Safety of the Dipeptidyl Peptidase-4 Inhibitor Alogliptin in Patients With Type 2 Diabetes and Inadequate Glycemic Control: A randomized, double-blind, placebo-controlled study
- (2008) R. A. DeFronzo et al. DIABETES CARE
- Efficacy and tolerability of vildagliptin in drug-nave patients with type 2 diabetes and mild hyperglycaemia
- (2008) W. A. Scherbaum et al. DIABETES OBESITY & METABOLISM
- Efficacy and Safety of Vildagliptin Monotherapy during 2-Year Treatment of Drug-naïve Patients with Type 2 Diabetes: Comparison with Metformin
- (2008) B. Göke et al. HORMONE AND METABOLIC RESEARCH
- Efficacy and safety of adding the dipeptidyl peptidase-4 inhibitor alogliptin to metformin therapy in patients with type 2 diabetes inadequately controlled with metformin monotherapy: a multicentre, randomised, double-blind, placebo-controlled study
- (2008) M. A. Nauck et al. INTERNATIONAL JOURNAL OF CLINICAL PRACTICE
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started